Dopamine versus norepinephrine in the treatment of shock

CJEM. 2011 Nov;13(6):395-7. doi: 10.2310/8000.2011.110297.

Abstract

Clinical question: Which vasopressor agent, norepinephrine or dopamine, is superior in the treatment of shock?

Article chosen: De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-89.

Study objective: The authors of this study set out to compare 28-day mortality in patients with shock who were treated with either dopamine or norepinephrine as initial vasopressor therapy. The authors' secondary outcome measures included mortality beyond 28 days and adverse events associated with each agent.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Dopamine / adverse effects
  • Dopamine / therapeutic use*
  • Double-Blind Method
  • Humans
  • Norepinephrine / adverse effects
  • Norepinephrine / therapeutic use*
  • Shock / drug therapy*
  • Shock, Cardiogenic / drug therapy
  • Survival Analysis
  • Vasoconstrictor Agents / adverse effects
  • Vasoconstrictor Agents / therapeutic use*

Substances

  • Vasoconstrictor Agents
  • Dopamine
  • Norepinephrine